PEA Palmitoylethanolamide with Levagen

Introduction

Palmitoylethanolamide (PEA), a compound derived from fat, possesses remarkable properties that contribute to its potential therapeutic benefits. This endogenous substance is naturally synthesized within the human body and can be found in various food sources like egg yolks and peanuts. Extensive research has highlighted the body’s increased production of PEA during disease states, underscoring its significance in maintaining overall health.

PEA has demonstrated compelling anti-inflammatory, anti-microbial, and neuroprotective properties. Its ability to bind to cells in the body enables it to effectively reduce pain and swelling. Clinical trials have yielded promising results, indicating that PEA has the potential to alleviate sleep disturbances, promote joint health, and accelerate the recovery process following injuries.

However, PEA with Levagen is not an FDA-approved medicine or dietary supplement which means it is not recommended for human consumption. Buy this product for research purposes only.

Palmitoylethanolamide PEA Product Details

Palmitoylethanolamide (PEA) is a fatty acid amide naturally produced within the body. It belongs to a group of lipid-soluble derivatives known as fatty acid amides, which play a crucial role in regulating various processes such as locomotion, sleep, and angiogenesis.

PEA can be found in several natural food sources, including egg yolks, peanuts, soybeans, alfalfa, and lecithin. It is also produced by many animals and plants. Since its discovery in the 1950s, PEA has garnered significant attention, leading to numerous randomized clinical trials and preclinical studies.

The research conducted on PEA has demonstrated its potential in reducing complex pain and facilitating recovery from stroke. Furthermore, it has shown promising results in reducing eye nerve damage, improving mood, and potentially enhancing the quality of life for patients with multiple sclerosis.

One notable aspect of PEA is its excellent clinical and preclinical safety record. Unlike other endocannabinoids, PEA’s breakdown products, namely palmitic acid and ethanol amine, do not produce side effects. This characteristic adds to its overall appeal as a therapeutic substance.

  • CAS Number 544-31-0
  • Molar Mass 299,49 g/mol-1
  • Chemical Formula C18H37NO2
  • IUPAC Name N-(2-Hydroxyethyl)hexadecanamide

Key Features of PEA Palmitoylethanolamide with Levagen

  • 98% Purity
  • 300mg/60ct/18g
  • Sold for research purposes only

Potential Benefits of Palmitoylethanolamide PEA

PEA and Multiple Sclerosis

While the effects of PEA as a standalone treatment for multiple sclerosis (MS) are yet to be explored, a trial examining PEA as an add-on therapy in rapidly advancing MS reported positive outcomes. Participants receiving oral PEA supplementation alongside conventional MS therapy experienced a reduction in adverse effects and pain, as well as improvements in quality of life and cognition. [R]

PEA and Neuroprotection

Clinical trials and cell models have demonstrated the neuroprotective effects of PEA. In patients suffering from acute ischemic stroke, PEA in combination with luteolin improved recovery, cognitive skills, overall brain health, and daily functioning. PEA treatment has also exhibited neuroprotective properties by reducing neuro-inflammation and attenuating the neurodegenerative consequences of amyloid-beta (AB) in cell models. [R] [R]

Furthermore, in animal models of Alzheimer’s disease, particularly with the use of ultra-micronized formulations of PEA, promising therapeutic effects have been observed. [R]

PEA and Glaucoma

Research indicates that PEA can have a positive impact on glaucoma, the second leading cause of blindness worldwide. Clinical trials have shown that oral PEA treatment significantly reduces intraocular pressure (IOP) in patients with raised IOP. These effects have been observed in patients with raised IOP due to different factors, and the reduction in IOP lasted even beyond the period of PEA consumption. Importantly, no adverse effects were reported during these studies. [R] [R]

PEA and Sleep

Clinical studies have investigated the potential of PEA as a sleeping aid. In a double-blind, placebo-controlled study involving individuals with sleep pattern disturbances, PEA was found to reduce sleep onset time and improve cognition upon waking. Another study focusing on patients awaiting carpal tunnel syndrome surgery demonstrated that PEA treatment significantly improved overall sleep quality, increasing continuous sleep time and reducing sleep disturbances. [R] [R]

PEA and Depression

PEA has been investigated as an adjunctive therapy for patients with major depressive disorder (MDD). In a study involving patients with MDD, PEA supplementation alongside citalopram (an antidepressant) effectively improved depressive symptoms. A higher percentage of patients in the PEA group responded to the treatment compared to the placebo group. [R] [R]

PEA and Pain Relief

Numerous clinical trials have investigated the pain-relieving properties of PEA, consistently demonstrating its efficacy in various pain conditions.

One certain research was designed to investigate PEA’s effect on temporomandibular joint inflammatory pain against nonsteroidal anti-inflammatory drugs. Interestingly, those who received PEA experienced a higher decrease in pain compared with those who were administered other drugs. [R]

For instance, a study involving test subjects with pelvic pain caused by endometriosis found that PEA treatment significantly relieved pain, improved sexual function, and enhanced overall quality of life. Similarly, in patients with sciatica pain that did not respond to traditional painkillers, a combination of PEA and Oxycodone treatment resulted in a significant decrease in pain levels. [R]

PEA has also shown promise in reducing nerve pain associated with carpal tunnel syndrome and alleviating pain and related symptoms in knee osteoarthritis. Additionally, PEA has been reported to provide relief in cancer pain, pain resulting from failed back surgery, and muscle pain associated with fibromyalgia. Importantly, none of these studies reported any significant side effects. [R] [R]

How It Works

Palmitoylethanolamide (PEA) utilizes various mechanisms of action to exert its effects on the body:

One of these mechanisms involves the activation of PPAR alpha, a protein known for its energy-boosting, fat-burning, and anti-inflammatory properties. By activating PPAR alpha, PEA inhibits the production and activity of inflammatory substances in the body, contributing to its overall health-improving capabilities.

Another mechanism involves the reduction of FAAH (fatty acid amide hydrolase) activity. FAAH is a protein-coding gene responsible for breaking down anandamide, an enzyme that helps the body alleviate pain and promote relaxation. By reducing FAAH activity, PEA allows anandamide to carry out its functions effectively, potentially leading to pain relief and increased relaxation.

Additionally, PEA interacts as an agonist with GPR119, a G protein-coupled receptor predominantly found in the pancreas and gastrointestinal tract. Through this interaction, PEA modulates GPR119 activity, which has shown promising effects on food intake, glucose homeostasis, and body weight regulation in in-vitro studies and animal models.

Precautions

When working with Palmitoylethanolamide (PEA) dietary supplements for research purposes, it is essential to adhere to certain precautions. Firstly, it should be emphasized that PEA is strictly intended for research use only and should not be consumed by humans or used for clinical applications, including diagnosis, treatment, or prevention of any disease or medical condition.

To ensure safety, researchers handling PEA should follow appropriate safety measures and protocols. This includes wearing personal protective equipment (PPE) such as gloves, lab coats, and safety glasses to minimize the risk of exposure. Adhering to good laboratory practices is crucial for the proper handling and disposal of PEA and any related materials.

Furthermore, researchers need to comply with all applicable laws, regulations, and institutional guidelines governing the use, storage, and transportation of PEA. This may involve obtaining necessary permits and approvals from relevant authorities before initiating any research involving PEA.

Proper storage is paramount to maintain the stability and integrity of PEA. Researchers should store PEA according to recommended conditions, taking into account factors such as temperature and light exposure. It is advisable to follow manufacturer instructions or established guidelines for the storage and handling of PEA to ensure accurate and reliable research results.

Potential Side Effects

The combination of Palmitoylethanolamide (PEA) with Levagen is generally regarded as safe with minimal reported side effects. PEA is a naturally occurring compound in the body.

However, it is important to note that personal reactions may vary, and some test subjects may experience mild gastrointestinal discomfort or allergic reactions. It is advisable to purchase this chemical made from high-quality ingredients manufactured by reputable brands.

Conclusion

In conclusion, the combination of Palmitoylethanolamide (PEA) with Levagen could offer numerous benefits for joint health and overall well-being. Studies have shown that this combination can increase plasma PEA concentration, leading to improved joint function and reduced joint pain. The use of Palmitoylethanolamide (PEA) with Levagen in various food and beverage applications is gaining recognition, thanks to its standard PEA formulation and increased bioavailability.

Clinical trials have demonstrated the efficacy of PEA with Levagen in managing chronic pain, including pelvic pain caused by endometriosis. The presence of PEA in natural sources like egg yolk further highlights its potential to promote restful sleep and dose-dependent improvement in various conditions.

Moreover, PEA with Levagen has shown promise in reducing mast cell degranulation, supporting immune health, and interacting with the endocannabinoid system to alleviate stress and anxiety. Unlike CBD, this combination is generally recognized as safe by the FDA, making it a safer alternative for individuals seeking natural solutions.

The clinically shown effects of PEA with Levagen on PPARα receptors further enhance its potential in supporting self-healing processes, aiding in sports recovery, and mitigating the impact of the injury. The lipid extracts of PEA with Levagen have been linked to its improved bioavailability, allowing for better absorption and utilization by the body.

Disclaimer:

Please take note of the scientific applications of this product and carefully read our Terms and Conditions before purchasing RCD.bio. By completing your order and submitting payment, you agree to abide by our Terms and Conditions. Please be aware that the product packaging may differ slightly from the images displayed on our website.

If for any reason you are not completely satisfied with the product you receive, please contact us at [email protected]. Our team is dedicated to ensuring customer satisfaction and will be happy to assist you.

PLEASE NOTE: All products offered by RCD.bio are strictly intended for laboratory and research purposes only. They are not intended for use on animals or humans.